Display options
Cite
Blundo C, Giroda M, Fusco N, et al. Early Breast Cancers During Pregnancy Treated With Breast-Conserving Surgery in the First Trimester of Gestation: A Feasibility Study. Front Oncol. 2021;11:723693doi: 10.3389/fonc.2021.723693.
Blundo, C., Giroda, M., Fusco, N., Sajjadi, E., Venetis, K., Leonardi, M. C., Vicini, E., Despini, L., Rossi, C. F., Runza, L., Sfondrini, M. S., Piciotti, R., Di Loreto, E., Scarfone, G., Guerini-Rocco, E., Viale, G., Veronesi, P., Buonomo, B., Peccatori, F. A., & Galimberti, V. E. (2021). Early Breast Cancers During Pregnancy Treated With Breast-Conserving Surgery in the First Trimester of Gestation: A Feasibility Study. Frontiers in oncology, 11723693. https://doi.org/10.3389/fonc.2021.723693
Blundo, Concetta, et al. "Early Breast Cancers During Pregnancy Treated With Breast-Conserving Surgery in the First Trimester of Gestation: A Feasibility Study." Frontiers in oncology vol. 11 (2021): 723693. doi: https://doi.org/10.3389/fonc.2021.723693
Blundo C, Giroda M, Fusco N, Sajjadi E, Venetis K, Leonardi MC, Vicini E, Despini L, Rossi CF, Runza L, Sfondrini MS, Piciotti R, Di Loreto E, Scarfone G, Guerini-Rocco E, Viale G, Veronesi P, Buonomo B, Peccatori FA, Galimberti VE. Early Breast Cancers During Pregnancy Treated With Breast-Conserving Surgery in the First Trimester of Gestation: A Feasibility Study. Front Oncol. 2021 Aug 24;11:723693. doi: 10.3389/fonc.2021.723693. eCollection 2021. PMID: 34504801; PMCID: PMC8421851.
Copy Download .nbib Format: NLM
Share it on

Front Oncol. 2021 Aug 24;11:723693. doi: 10.3389/fonc.2021.723693. eCollection 2021.

Early Breast Cancers During Pregnancy Treated With Breast-Conserving Surgery in the First Trimester of Gestation: A Feasibility Study.

Frontiers in oncology

Concetta Blundo, Massimo Giroda, Nicola Fusco, Elham Sajjadi, Konstantinos Venetis, M Cristina Leonardi, Elisa Vicini, Luca Despini, Claudia F Rossi, Letterio Runza, Maria S Sfondrini, Roberto Piciotti, Eugenia Di Loreto, Giovanna Scarfone, Elena Guerini-Rocco, Giuseppe Viale, Paolo Veronesi, Barbara Buonomo, Fedro A Peccatori, Viviana E Galimberti

Affiliations

  1. Breast Surgery Unit, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan, Italy.
  2. Division of Pathology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
  3. Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
  4. Division of Radiotherapy, IEO, European Institute of Oncology IRCCS, Milan, Italy.
  5. Division of Breast Surgery, IEO, European Institute of Oncology IRCCS, Milan, Italy.
  6. Division of Pathology, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan, Italy.
  7. Breast Imaging Unit, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan, Italy.
  8. Gynecology Unit, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan, Italy.
  9. Fertility and Procreation Unit, Division of Gynecologic Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy.

PMID: 34504801 PMCID: PMC8421851 DOI: 10.3389/fonc.2021.723693

Abstract

Breast cancer is the most common malignancy occurring during gestation. In early-stage breast cancer during pregnancy (PrBC), breast-conserving surgery (BCS) with delayed RT is a rational alternative to mastectomy, for long considered the standard-of-care. Regrettably, no specific guidelines on the surgical management of these patients are available. In this study, we investigated the feasibility and safety of BCS during the first trimester of pregnancy in women with early-stage PrBC. All patients with a diagnosis of PrBC during the first trimester of pregnancy jointly managed in two PrBC-specialized Centers were included in this study. All patients underwent BCS followed by adjuvant radiotherapy to the ipsilateral breast after delivery. Histopathological features and biomarkers were first profiled on pre-surgical biopsies. The primary outcome was the isolated local recurrence (ILR). Among 168 PrBC patients, 67 (39.9%) were diagnosed during the first trimester of gestation. Of these, 30 patients (age range, 23-43 years; median=36 years; gestational age, 2-12 weeks; median=7 weeks; median follow-up time=6.5 years) met the inclusion criteria. The patients that were subjected to radical surgery (n=14) served as controls. None of the patients experienced perioperative surgical complications. No ILR were observed within three months (n=30), 1 year (n=27), and 5 years (n=18) after surgery. Among the study group, 4 (12.3%) patients experienced ILR or new carcinomas after 6-13 years, the same number (n=4) had metastatic dissemination after 3-7 years. These patients are still alive and disease-free after 14-17 years of follow-up. The rate of recurrences and metastasis in the controls were not significantly different. The findings provide evidence that BCS in the first trimester PrBC is feasible and reasonably safe for both the mother and the baby.

Copyright © 2021 Blundo, Giroda, Fusco, Sajjadi, Venetis, Leonardi, Vicini, Despini, Rossi, Runza, Sfondrini, Piciotti, Di Loreto, Scarfone, Guerini-Rocco, Viale, Veronesi, Buonomo, Peccatori and Galimberti.

Keywords: breast cancer during pregnancy; breast-conserving surgery; early stage; early-onset breast cancer; pregnancy-associated breast cancer

Conflict of interest statement

NF has received honoraria for consulting, advisory role, honoraria, travel, accommodation, and/or speaker bureau from Merck Sharp & Dohme (MSD), Boehringer Ingelheim, and Novartis. ER has received adv

References

  1. Breast. 2019 Apr;44:15-23 - PubMed
  2. Ann Oncol. 2013 Oct;24 Suppl 6:vi160-70 - PubMed
  3. Eur Rev Med Pharmacol Sci. 2020 Aug;24(15):8028-8035 - PubMed
  4. Phys Med. 2017 Nov;43:148-152 - PubMed
  5. Acta Oncol. 2012 May;51(5):653-61 - PubMed
  6. Obstet Gynecol. 2009 Sep;114(3):568-572 - PubMed
  7. Lancet Oncol. 2005 May;6(5):328-33 - PubMed
  8. ESMO Open. 2016 May 4;1(3):e000016 - PubMed
  9. Breast Care (Basel). 2017 Dec;12(6):396-400 - PubMed
  10. Oncologist. 2011;16(11):1547-51 - PubMed
  11. Eur J Cancer. 1995 Sep;31A(10):1574-9 - PubMed
  12. Histopathology. 1991 Nov;19(5):403-10 - PubMed
  13. Eur J Cancer. 2010 Dec;46(18):3158-68 - PubMed
  14. J Womens Health (Larchmt). 2019 Jun;28(6):778-784 - PubMed
  15. JAMA Oncol. 2016 Mar;2(3):302-4 - PubMed
  16. BMC Pregnancy Childbirth. 2018 Nov 26;18(1):460 - PubMed
  17. Best Pract Res Clin Obstet Gynaecol. 2016 May;33:2-18 - PubMed
  18. Front Oncol. 2020 Jun 16;10:864 - PubMed
  19. J Gynecol Obstet Hum Reprod. 2018 May;47(5):205-207 - PubMed
  20. Cancer Biol Med. 2018 Feb;15(1):6-13 - PubMed
  21. Cancer Manag Res. 2020 Jan 30;12:675-686 - PubMed
  22. Int J Cancer. 1996 Sep 17;67(6):751-5 - PubMed
  23. Cancers (Basel). 2020 Dec 03;12(12): - PubMed
  24. Clin Transl Oncol. 2005 Dec;7(11):499-503 - PubMed
  25. Breast Cancer Res Treat. 2013 May;139(1):183-92 - PubMed
  26. EPMA J. 2018 Jun 24;9(3):257-270 - PubMed
  27. Eur J Cancer. 2006 Jan;42(2):126-40 - PubMed
  28. Med Sci Monit. 2019 Nov 14;25:8587-8594 - PubMed
  29. Ann Oncol. 2004 Sep;15(9):1348-51 - PubMed
  30. Eur J Obstet Gynecol Reprod Biol. 2018 Nov;230:222-227 - PubMed
  31. Obstet Gynecol. 1996 Mar;87(3):414-8 - PubMed
  32. Radiother Oncol. 2008 Apr;87(1):3-16 - PubMed
  33. Best Pract Res Clin Obstet Gynaecol. 2016 May;33:79-85 - PubMed
  34. Cancer Treat Rev. 2012 Nov;38(7):834-42 - PubMed
  35. Cancers (Basel). 2019 Oct 28;11(11): - PubMed
  36. J Clin Oncol. 2005 Mar 20;23(9):1934-40 - PubMed
  37. Am J Transplant. 2018 May;18(5):1059-1067 - PubMed
  38. Cancer Treat Rev. 2010 Oct;36(6):443-50 - PubMed
  39. Front Oncol. 2020 Nov 18;10:620574 - PubMed
  40. Cancer Epidemiol. 2013 Oct;37(5):544-9 - PubMed
  41. Oncologist. 2002;7(4):279-87 - PubMed
  42. Ann ICRP. 2003;33(1-2):5-206 - PubMed
  43. Breast Dis. 2015;35(3):157-66 - PubMed
  44. Ann Oncol. 2010 May;21 Suppl 5:v266-73 - PubMed
  45. Breast. 2016 Dec;30:215-216 - PubMed

Publication Types